Australian Technical Advisory Group on Immunisation (ATAGI) advice for immunisation providers regarding the administration of seasonal influenza vaccines in 2017

Australia
NITAGs
6 March 2017

During its 62nd meeting in February 2017, ATAGI endorsed its recommendation for annual influenza vaccination for any person ≥6 months of age who wishes to reduce the likelihood of becoming ill with influenza.

drapeau-australie.jpg

Key points:

  • Annual vaccination is the most important measure to prevent influenza and its complications.
  • Annual influenza vaccination is recommended for any person ≥6 months of age who wishes to reduce the likelihood of becoming ill with influenza.
  • Recent evidence suggests protection against influenza may start to decrease from 3 to 4 months following vaccination and early vaccination needs to be balanced with this. While influenza continues to circulate, it is never too late to vaccinate.
  • Only quadrivalent influenza vaccines (QIV) formulations are available in Australia in 2017. Age restrictions apply according to vaccine brand (refer to Table 1).
  • QIVs are funded on the National Immunisation Program (NIP) in 2017 for the following groups:
    • Aboriginal and/or Torres Strait Islander children aged 6 months to <5 years
    • Aboriginal and/or Torres Strait Islander persons aged ≥15 years
    • All persons aged ≥65 years
    • All persons aged ≥6 months who have certain medical conditions which increase the isk of influenza disease complications; for example, severe asthma, lung or heart disease, low immunity or diabetes (refer to Table 3).
    • Pregnant women (during any stage of pregnancy).
  • Influenza vaccination is also strongly recommended, but not funded, for other groups who are at increased risk of influenza and its complications (refer to Table 3 footnote).
  • Persons with egg allergy, including anaphylaxis, can be safely vaccinated with influenza vaccines. Persons with a history of anaphylaxis to egg can be vaccinated with a full vaccine dose in medical facilities with staff experienced in recognising and treating anaphylaxis.
  • Providers are reminded to report all vaccines given to the Australian Immunisation Register.
Documents to download

Related News & Events

  • WHO China
    Beijing, P.R. China
  • Kazakhstan
    NITAGs

    Voice from the field : Lyazzat Yeraliyeva

    14.11.2017

    The NITAG of Kazakhstan recently launched their website to make their recommendations available and promote the work of the members. Lyazzat Yeraliyeva, former Chair of the NITAG, now acts as the Deputy Chair.

    Read more
  • NITAGs

    Strenghtening NITAGs through the Partnership for Influenza Vaccine Introduction

    07.11.2017

    The Partnership for Influenza Vaccine Introduction (PIVI), based at The Task Force for Global Health (TFGH), is an innovative public/private program that partners with the Centers for Disease Control and Prevention (CDC), Ministries of Health, corporate partners and others to create sustainable, routine, seasonal influenza vaccination programs in low- and middle-income countries.   PIVI’s goal is to create routine, seasonal influenza vaccination programs to protect communities from the impacts of both seasonal and pandemic influenza. Working with countries’ Ministries of Health, as well as with other technical collaborators, PIVI supports capacity building for NITAGs to make evidence-based vaccine policy decision making.  These activities are coordinated with NITAG strengthening work carried out through other projects and cooperative funding agreements between countries and CDC’s Influenza and Global Immunization Divisions.  The work is also closely coordinated with NITAG focal points in WHO regional and country offices.  

    Read more